OR WAIT 15 SECS
Key learnings from the BCG Market Access benchmark 2019.
Since 2013, the BCG Market Access Roundtable has been conducting a comprehensive benchmark of Market Access-related activities every three years. In 2019 we conducted our third benchmark which covered the ‘traditional’ Market Access (MA) activities (e.g. pricing, Health Economics (HE), Outcomes Research (OR)), and also activities that interface with other functions, namely health policy and real world evidence (RWE).
The 2019 benchmark is based on quantitative data from the 14 participating companies and over 100 interviews conducted with market access, public policy, and RWE leaders from across global, regional and nine local markets: US, EU5, China, Brazil, and Japan. In addition, we ran a structured survey with over 40 questions and synthesized the response of about 400 participants. The detailed results containing over 40 analyses are documented in five chapters: Key insights, Organization, Resourcing, Governance, and Capabilities and shared with the participating companies.
In this publication we highlight key observations from the 2019 benchmark which include 10 industry level insights; deep dives on five hot topics identified, and 10 capabilities that were seen to be critical for the future success of the MA function.
In distilling through the various interviews and survey results we found that a key priority that cuts across all leadership (Market Access, Public Policy and Real World Evidence) groups we talked to was sourcing, developing, and retaining Market Access talent and capabilities.
The BCG Market Access Roundtable had already identified talent and capability development as a key priority in its first benchmark in 2013 and based on that work had developed a comprehensive framework on MA competencies.1
Subsequently, the BCG Market Access Roundtable also pioneered the set-up of an executive training course in collaboration with the London School of Economics (which is now in its 3rd year of delivery). Given the fact that this has been highlighted again as a key priority and recognizing that a lot has changed in the last decade, the BCG Market Access Roundtable has launched a new working group to tackle the topic and will provide recommendations by the end of 2020.
Aside from highlighting the need to improve the collaboration across these three sub-functions, six other priorities which fall in the cross-over between two functions was also highlighted and is elucidated in Figure 2.
For our benchmark, we focus on seven key MA activities, five of which are typically within the core of Market Access functions (pricing, health technology assessment (HTA), health economics (HE) , outcomes research (OR) and health policy), and two closely related activities (public policy and government affairs (PPGA), and Real World Evidence (RWE)).
Comparing how the seven key MA activities are anchored across the different companies we identified five key trends that are worth noting:
We do not observe a dominant organizational design for ‘traditional’ MA activities (e.g. pricing, HEOR), and activities at interface with other functions, namely health policy and RWE. Having said that, we found it helpful to look at two dimensions along which companies have made trade-off choices:
Degree of centralization vs. de-centralization: There is a wide spread in the level of centralization versus de-centralization (~1.26x above and below the average) driven by the overall context of the company (e.g. portfolio mix, commercial structures, strategic focus). However, there are two general trends we can observe: a) there is overall tendency to reduce regional/global resourcing in favor of local and b) increasing resources in China.
Functional set-up vs. anchoring by therapeutic areas (TA): There is an even higher variation along this dimension driven by distinct choices made by each company to address their specific current challenges. Interviewed MA leaders also made it clear that there was a general expectation that more changes are to come as strategic focus and portfolio/TA mix evolves. In addition, we found that while there is a wide spread in how functional resources are deployed (~1.44x above and below the average), there was a slight overall shift in the functional focus-with increased resources in customer facing activities, in particular those that are local, and gaining efficiency in backend activities like HE/HTA modeling.
In the 2016 benchmark, virtually all companies increased their resourcing across the board. In 2019, the picture is more nuanced with some companies continuing to increase their resources (either started later or from a lower base) while others are optimizing existing resource through differentiated deployment. For example, the regional layer is losing favor at about a third of companies. Others are exploring ‘agile’ or ‘new ways of working’ allowing for greater flexibility of resource deployment, which generally also results in fewer regional alignment roles.
As in the other years, we also looked at the overall resourcing of MA function across global, regional and local deployment and found two distinct scaling factors at play:
The scaling by launch needs and sales also allows to control for the differences in TA focus, portfolio, size, and other factors. The close alignment to the regression outlines the validity of the two scaling factors.
As has been noted in the previous benchmark and continued discussions at the BCG Market Access Roundtable, Integrated Evidence Planning (IEP) has emerged as a key joint process to align evidence generation activities across MA, medical, development, RWE, and regulatory early and across the product life cycle.
Integrating the evidence generation activities ensures the right evidence package is built for a product accounting for all stakeholders in the most effective/efficient way. This requires driving alignment on aspects of target product profile and trial design between functions to ensure right choices are made across functions vs. within a function only.
Most companies have deployed one form or another of IEP, although they are at differing levels of integration, sophistication, and maturity. At earlier stages of integration, companies still develop functional evidence generation plans bottom-up, and bring those plans together into an ‘integrated’ plan later. While this is a good starting basis it does not allow for the most efficient use of resources. In addition, we notice that involvement of countries (timing and number) varies across the companies and is less systematic in terms of the involvement of smaller yet progressive countries.
Close to 400 MA colleagues from global, region, and the nine largest countries outlined what they perceive to be the key capabilities for future success. Ten capabilities stood out, covering “traditional” aspects of MA such as health policy, evidence generation and synthesis, pricing, as well as broader themes such as organizational effectiveness (Figure 7).
Looking across the top 10 capabilities, two key themes emerge: Evidence generation and synthesis, and collaboration/co-creation.
More than half the capabilities relate to collaborating and co-creating with both internal and external stakeholders. As MA is becoming even more of a cross-functional endeavor, more MA objectives can only be achieved through support and collaboration from other functions. Consequently, the ability to steer the whole organization towards achieving MA goals becomes more complex. Hence more capabilities in this regards are required.
With access becoming the front and center issue for pharma companies, “Access” is part of the agenda of multiple different functions, and the role of the MA function is evolving rapidly.
With the increased importance comes a greater need to more closely collaborate with other functions and drive the larger organization towards achieving the company’s Access objectives. At the same time, other functions are building their Access focus and capabilities. Hence Access activities are no longer limited to the MA function only, and while the reach of Access is increasing, the remit of the MA function is blurring.
The MA function will need to refine their focus and rethink the way they interact with internal (and external) counterparts and stakeholders.
In a subsequent publication, the BCG Market Access Roundtable will explore further how the role of Access is evolving, and provide a perspective of how Market Access functions will need to set themselves up differently to succeed going forward.
1. Published earlier, http://www.pharmexec.com/building-market-access-competencies-future